The relative contribution of monoamine oxidase and cytochrome P450 lsozymes to the metabolic deamination of the trace amine tryptamine

Aiming Yu, Camille P. Granvil, Robert L. Haining, Kristopher W. Krausz, Javier Corchero, Adrian Küpfer, Jeffrey R. Idle, Frank J. Gonzalez

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Tryptamine is a trace amine in mammalian central nervous system that interacts with the trace amine TA2 receptor and is now thought to function as a neurotransmitter or neuromodulator. It had been reported that deamination of tryptamine to tryptophol was mediated by CYP2D6, a cytochrome P450 that is expressed in human brain, suggesting that tryptamine may be an endogenous substrate for this polymorphic enzyme. We were unable to confirm this report and have reinvestigated tryptamine metabolism in human liver microsomes (HLM) and in microsomes expressing recombinant human cytochrome P450 and monoamine oxidase (MAO) isozymes. Tryptamine was oxidized to indole-3-acetaldehyde by HLM and recombinant human MAO-A in the absence of NADPH, and indole-3-acetaldehyde was further reduced to tryptophol by aldehyde reductase in HLM in the presence of NADPH. Steady-state kinetic parameters were estimated for each reaction step by HLM and MAO-A. The CYP2D6 substrates bufuralol and debrisoquine showed strong inhibition of both tryptophol production from tryptamine in HLM and the formation of indole-3-acetaldehyde from tryptamine catalyzed by recombinant MAO-A. Anti-CYP2D6 monoclonal antibody did not inhibit these reactions. Pargyline, a nonselective MAO inhibitor, did not show cross inhibition to debrisoquine 4-hydroxylation and dextromethorphan O-demethylation by HLM and recombinant CYP2D6 enzyme. This is the first unequivocal report of the selective conversion of tryptamine to tryptophol by MAO-A. CYP2D6 does not contribute to this reaction.

Original languageEnglish (US)
Pages (from-to)539-546
Number of pages8
JournalJournal of Pharmacology and Experimental Therapeutics
Volume304
Issue number2
DOIs
StatePublished - Feb 1 2003
Externally publishedYes

Fingerprint

Deamination
Monoamine Oxidase
Cytochrome P-450 Enzyme System
Amines
Liver Microsomes
Cytochrome P-450 CYP2D6
Debrisoquin
NADP
Neurotransmitter Agents
Pargyline
Dextromethorphan
Aldehyde Reductase
Monoamine Oxidase Inhibitors
tryptamine
Electron Transport Complex IV
Enzymes
Hydroxylation
Microsomes
Isoenzymes
Central Nervous System

ASJC Scopus subject areas

  • Pharmacology

Cite this

The relative contribution of monoamine oxidase and cytochrome P450 lsozymes to the metabolic deamination of the trace amine tryptamine. / Yu, Aiming; Granvil, Camille P.; Haining, Robert L.; Krausz, Kristopher W.; Corchero, Javier; Küpfer, Adrian; Idle, Jeffrey R.; Gonzalez, Frank J.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 304, No. 2, 01.02.2003, p. 539-546.

Research output: Contribution to journalArticle

Yu, Aiming ; Granvil, Camille P. ; Haining, Robert L. ; Krausz, Kristopher W. ; Corchero, Javier ; Küpfer, Adrian ; Idle, Jeffrey R. ; Gonzalez, Frank J. / The relative contribution of monoamine oxidase and cytochrome P450 lsozymes to the metabolic deamination of the trace amine tryptamine. In: Journal of Pharmacology and Experimental Therapeutics. 2003 ; Vol. 304, No. 2. pp. 539-546.
@article{daf55b90fba64fd9aa2ebcd23e078c87,
title = "The relative contribution of monoamine oxidase and cytochrome P450 lsozymes to the metabolic deamination of the trace amine tryptamine",
abstract = "Tryptamine is a trace amine in mammalian central nervous system that interacts with the trace amine TA2 receptor and is now thought to function as a neurotransmitter or neuromodulator. It had been reported that deamination of tryptamine to tryptophol was mediated by CYP2D6, a cytochrome P450 that is expressed in human brain, suggesting that tryptamine may be an endogenous substrate for this polymorphic enzyme. We were unable to confirm this report and have reinvestigated tryptamine metabolism in human liver microsomes (HLM) and in microsomes expressing recombinant human cytochrome P450 and monoamine oxidase (MAO) isozymes. Tryptamine was oxidized to indole-3-acetaldehyde by HLM and recombinant human MAO-A in the absence of NADPH, and indole-3-acetaldehyde was further reduced to tryptophol by aldehyde reductase in HLM in the presence of NADPH. Steady-state kinetic parameters were estimated for each reaction step by HLM and MAO-A. The CYP2D6 substrates bufuralol and debrisoquine showed strong inhibition of both tryptophol production from tryptamine in HLM and the formation of indole-3-acetaldehyde from tryptamine catalyzed by recombinant MAO-A. Anti-CYP2D6 monoclonal antibody did not inhibit these reactions. Pargyline, a nonselective MAO inhibitor, did not show cross inhibition to debrisoquine 4-hydroxylation and dextromethorphan O-demethylation by HLM and recombinant CYP2D6 enzyme. This is the first unequivocal report of the selective conversion of tryptamine to tryptophol by MAO-A. CYP2D6 does not contribute to this reaction.",
author = "Aiming Yu and Granvil, {Camille P.} and Haining, {Robert L.} and Krausz, {Kristopher W.} and Javier Corchero and Adrian K{\"u}pfer and Idle, {Jeffrey R.} and Gonzalez, {Frank J.}",
year = "2003",
month = "2",
day = "1",
doi = "10.1124/jpet.102.043786",
language = "English (US)",
volume = "304",
pages = "539--546",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

TY - JOUR

T1 - The relative contribution of monoamine oxidase and cytochrome P450 lsozymes to the metabolic deamination of the trace amine tryptamine

AU - Yu, Aiming

AU - Granvil, Camille P.

AU - Haining, Robert L.

AU - Krausz, Kristopher W.

AU - Corchero, Javier

AU - Küpfer, Adrian

AU - Idle, Jeffrey R.

AU - Gonzalez, Frank J.

PY - 2003/2/1

Y1 - 2003/2/1

N2 - Tryptamine is a trace amine in mammalian central nervous system that interacts with the trace amine TA2 receptor and is now thought to function as a neurotransmitter or neuromodulator. It had been reported that deamination of tryptamine to tryptophol was mediated by CYP2D6, a cytochrome P450 that is expressed in human brain, suggesting that tryptamine may be an endogenous substrate for this polymorphic enzyme. We were unable to confirm this report and have reinvestigated tryptamine metabolism in human liver microsomes (HLM) and in microsomes expressing recombinant human cytochrome P450 and monoamine oxidase (MAO) isozymes. Tryptamine was oxidized to indole-3-acetaldehyde by HLM and recombinant human MAO-A in the absence of NADPH, and indole-3-acetaldehyde was further reduced to tryptophol by aldehyde reductase in HLM in the presence of NADPH. Steady-state kinetic parameters were estimated for each reaction step by HLM and MAO-A. The CYP2D6 substrates bufuralol and debrisoquine showed strong inhibition of both tryptophol production from tryptamine in HLM and the formation of indole-3-acetaldehyde from tryptamine catalyzed by recombinant MAO-A. Anti-CYP2D6 monoclonal antibody did not inhibit these reactions. Pargyline, a nonselective MAO inhibitor, did not show cross inhibition to debrisoquine 4-hydroxylation and dextromethorphan O-demethylation by HLM and recombinant CYP2D6 enzyme. This is the first unequivocal report of the selective conversion of tryptamine to tryptophol by MAO-A. CYP2D6 does not contribute to this reaction.

AB - Tryptamine is a trace amine in mammalian central nervous system that interacts with the trace amine TA2 receptor and is now thought to function as a neurotransmitter or neuromodulator. It had been reported that deamination of tryptamine to tryptophol was mediated by CYP2D6, a cytochrome P450 that is expressed in human brain, suggesting that tryptamine may be an endogenous substrate for this polymorphic enzyme. We were unable to confirm this report and have reinvestigated tryptamine metabolism in human liver microsomes (HLM) and in microsomes expressing recombinant human cytochrome P450 and monoamine oxidase (MAO) isozymes. Tryptamine was oxidized to indole-3-acetaldehyde by HLM and recombinant human MAO-A in the absence of NADPH, and indole-3-acetaldehyde was further reduced to tryptophol by aldehyde reductase in HLM in the presence of NADPH. Steady-state kinetic parameters were estimated for each reaction step by HLM and MAO-A. The CYP2D6 substrates bufuralol and debrisoquine showed strong inhibition of both tryptophol production from tryptamine in HLM and the formation of indole-3-acetaldehyde from tryptamine catalyzed by recombinant MAO-A. Anti-CYP2D6 monoclonal antibody did not inhibit these reactions. Pargyline, a nonselective MAO inhibitor, did not show cross inhibition to debrisoquine 4-hydroxylation and dextromethorphan O-demethylation by HLM and recombinant CYP2D6 enzyme. This is the first unequivocal report of the selective conversion of tryptamine to tryptophol by MAO-A. CYP2D6 does not contribute to this reaction.

UR - http://www.scopus.com/inward/record.url?scp=0037310739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037310739&partnerID=8YFLogxK

U2 - 10.1124/jpet.102.043786

DO - 10.1124/jpet.102.043786

M3 - Article

C2 - 12538805

AN - SCOPUS:0037310739

VL - 304

SP - 539

EP - 546

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 2

ER -